and for "interest"
1 rec
Ivyspivey
Posts: 12,642
Price: 9.45
No Opinion
Cohort 41 Feb 2025 13:32
FAO Burble or anyone.
What are peoples thoughts on why SCLP have decided to run Cohort 4?
It seemed to be decided at a later stage and not part of the original plan so why the apparent change of heart.
Interested in peoples thoughts |
Very Good Ruck ....
but i don't spend Hours writing Glossy articles for "woke daily"
i expect Investors here to have at least read the basics
like Immunobody is both a Therapeutic and prophylactic vaccine considering the "experts" have been on these BB's since Lozan retired in 1960
and Scancell patent is at least 355 years old ... Carved on a cave Wall by the Hairy Bikers
Fun text ... 🤣🙄 |
next point
as Scancell has told you
SCIB1 penetration is a 1$ billion
but the cost of sales is probably about £30 per injection
thats a lot of head room to lower the price and still make serious money
if a bio similar was ever to be marketed.
so to much time spent on "irrelevance"
because Chapati will go after bigger fish "keytruda" |
 Inan, I'm not sure any of us can go through another day reading your unintelligible, cryptic, broken English posts (whether accurate ir not, interesting or not)Perhaps I could translate for you? Is this what you are trying to communicate?........,When you create a generic drug, the idea is to offer it at a lower price compared to the branded version, making it more affordable. However, to make it profitable, you need to sell it in large quantities-a high volume-because the profit margin on each unit is smaller.For common medications, like heart pills, the market is huge. Millions, if not billions, of people need them. So, even with a lower price, the high sales volume makes it profitable.On the other hand, orphan drugs are used to treat rare diseases. The market for these drugs is much smaller because fewer people need them. This means you can't rely on volume to make up for lower prices. Orphan drugs often remain expensive because the development costs need to be recouped from a smaller group of patients, and they might not benefit from the same volume-driven cost reductions that generics for common conditions do.It's a complex balance between making drugs affordable and ensuring pharmaceutical companies can cover their costs and continue to innovate. |
how many companies use Rolls Royce off patent engines ?
RB211 etc |
Now the next interesting point ...
if you build a generic
and you vastly lower the price
you need Volume of sales to make it profitable
so Heart pills etc billions sold
an orphan drug not so many .... |
Well its all a bit simple
1997-09-04
Publication of WO1997032021A1
so you said Lindy Durrant did not invent it yesterday WRONG
Ian Spendlove Richard Adrian Robins Lindy Gillian Durrant (inventors)
so the original patent Has clearly expired
so if like you said we will get Bio Similar because its off patent which could be developed further
can you name 1 ?
next problem its not approved so any use will require the usual 7 years of exhaustive research and MONEY including Trials ...
Mr Chapati from India .. thinks thats all a bit to much !!
because he wants to target Off Patent drugs that have been approved
plenty of then around
So He just waits at the cliffs of Dover ... you don't even need a passport, its a free entry port inc shoes. clothes. food. house and Fast track use of the NHS and the patent falls into his lap
via the post office Patent Cliff service |
Forgotten more science than you'll ever know.....and infinitely better with markets.
That's why I know.....not much to see here....
Hence price.... |
Thats OK Ivy ...
Lozan is able to translate ""Latent heat"" into something it isn't
you are not alone !!
that's why i gave Lozan the job !
he is also the BB scam detective ... |
yes Mr Liar .... also known as baby Buffet
2 becomes 1 ..........
you little cheat
typical salesman |
FFS I can’t help if you don’t understand common terminology.
That is the problem you think you know but you know c@&k all but are so thick you don’t realise it |
which also means ....
competition to partner
exclusive will cost big |
also it does not tie it down to a single manufacturer
they use the "Ligand" as the description |
that was a handy discovery Marcus ...
so Modi1 will get new patents as well ... |
On the LSE Ivy ... apart from a direction to an earlier post by chester
why is it nobody replied to you ? |
Lozan can you translate that for us ...
""We all know that but I specifically asked you where status of the Infectious Disease element was."" |
now on your last post
change of plan ... 2 platforms become 1
"""You point out the obvious that the Immunobody platform was designed for oncology but used vs ID during Covid times. We all know that but I specifically asked you where status of the Infectious Disease element was."""
So you lied !!
add to that
""We all know that but I specifically asked you where status of the Infectious Disease element was.""
"dreadful communication and shocking poor English" |
Last vaccine I helped develop for a small company was a weakened one...live attenuated.
It did get to market.
Used particularly in the UK.
Did absolutely nothing for the company share price
.
.
This isn't a risky stock....it's massively risky. |
so here on this post you are still describing two platforms
Ivyspivey1 Feb '25 - 17:58 - 17140 of 17154
0 3 0
Nana you did not answer my simple question as you could not answer it.
Instead you post that SCLP ID (Infectious Disease) Platform is being used for SCIB1 and iSCIB which I thought were using an oncology platform.
You really get mixed up easily. |
and just to repeat your post
Ivyspivey - 31 Jan 2025 - 11:56:49 - 16927 of 17153 Scancell - Pot of Gold or POS? - SCLP
You know perfectly well that we were both referring to an Infectious disease Vax platform not oncology.
Please let me know where the status of SCLP ID Vax Platform is now.?
you clearly are describing 2 platforms
Cancer
and
infectious disease |
Bermudashorts
RE: Cohort 4Today 15:19
Sci102
SCIB1 patent hasn't expired yet (think it's 2027 or 2028 but would need to check) and it doesn't have orphan drug status in Europe or any of the other major markets -just the US as far as I'm aware. Following your strategy means that they'd have to take SCIB1 all the way through phase 2/3 randomised trials, submit for approval and then ramp up sales and marketing to try and make the commercials work within the 7 year period without protection in ROW.
If they decided to go with iSCIB1+ for HLA A2 patients only then you're right, SCIB1 would be off patent, however it wouldn't have marketing approval so anyone wanting to copy would have to take their version through the whole development process including clinical trials and seek regulatory approval - would take several years and be way behind iSCIB1+.
Should also point out that Scancell have confirmed that they've filed for a new SCIB1 patent in combination with CPIs. I know you believe that won't be granted - time will tell!
The reality is of course that we simply have no idea yet how iSCIB1+ is performing in the clinic and it's going to be fascinating to see how this plays out. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
